| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | UBE2V2 |
| Uniprot No | Q15819 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-145aa |
| 氨基酸序列 | AVSTGVKVPRNFRLLEELEEGQKGVGDGTVSWGLEDDEDMTLTRWTGMIIGPPRTNYENRIYSLKVECGPKYPEAPPSVRFVTKINMNGINNSSGMVDARSIPVLAKWQNSYSIKVVLQELRRLMMSKENMKLPQPPEGQTYNN |
| 预测分子量 | 32.2kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于UBE2V2重组蛋白的模拟参考文献示例(仅供参考，实际文献需通过学术数据库查询)：
---
1. **文献名称**：*UBE2V2 Recombinant Protein Modulates p53 Ubiquitination in Colorectal Cancer*
**作者**：Chen L, Wang Y, et al.
**摘要**：研究通过体外表达UBE2V2重组蛋白，揭示了其与E3连接酶协同促进肿瘤抑制蛋白p53的泛素化降解，从而增强结直肠癌细胞化疗耐药性的机制。
2. **文献名称**：*Structural and Functional Analysis of UBE2V2 in the Ubiquitin-Proteasome Pathway*
**作者**：Kimura T, Sato M, et al.
**摘要**：利用重组UBE2V2蛋白进行X射线晶体学分析，解析其与泛素结合的关键结构域，并证明其在体外泛素链延伸中的催化活性依赖于特定赖氨酸残基。
3. **文献名称**：*UBE2V2 Overexpression via Recombinant Protein Delivery Exacerbates Inflammatory Signaling in Macrophages*
**作者**：Gupta R, Patel S, et al.
**摘要**：实验表明，重组UBE2V2蛋白通过增强TRAF6介导的NF-κB通路泛素化，促进巨噬细胞中促炎因子(如TNF-α和IL-6)的释放，提示其在自身免疫疾病中的潜在作用。
4. **文献名称**：*UBE2V2 Recombinant Protein as a Biomarker for Neurodegenerative Disease Progression*
**作者**：Müller J, Schneider A, et al.
**摘要**：在帕金森病模型中，重组UBE2V2蛋白被用于验证其与α-突触核蛋白异常聚集的相关性，表明其可能通过调控错误蛋白清除影响疾病进程。
---
**注**：以上为模拟生成的参考文献，实际研究中请通过PubMed、Web of Science等平台检索具体文献。
**Background of UBE2V2 Recombinant Protein**
UBE2V2 (Ubiquitin-Conjugating Enzyme E2 V2), also known as MMS2. is a member of the ubiquitin-conjugating E2 enzyme family. It plays a critical role in the ubiquitination pathway, a post-translational modification process essential for protein degradation, signal transduction, and DNA repair. Unlike typical E2 enzymes, UBE2V2 lacks a catalytic cysteine residue, requiring interaction with a partner E2 enzyme (e.g., UBE2N/UBC13) to form an active heterodimer. This complex mediates K63-linked polyubiquitination, a non-proteolytic modification involved in inflammatory signaling, NF-κB activation, and error-free DNA damage repair via the homologous recombination pathway.
The recombinant UBE2V2 protein is produced through *in vitro* expression systems (e.g., *E. coli* or mammalian cells) to ensure high purity and functionality. It retains the ability to bind UBE2N and participate in ubiquitin transfer, making it a valuable tool for studying enzymatic mechanisms, protein-protein interactions, and regulatory networks in cellular stress responses. Researchers utilize UBE2V2 recombinant protein to investigate its role in diseases linked to dysregulated ubiquitination, such as cancers, neurodegenerative disorders, and autoimmune conditions.
Structural studies of UBE2V2 have revealed insights into its ubiquitin-binding domains and conformational dynamics, though challenges remain in crystallizing full-length complexes due to intrinsic flexibility. Beyond basic research, UBE2V2 is explored as a potential therapeutic target, particularly in oncology, where modulating K63-linked ubiquitination could influence tumor progression or chemotherapy resistance. Overall, UBE2V2 recombinant protein serves as a pivotal resource for dissecting the complexities of ubiquitin-dependent cellular regulation and developing targeted therapies.
×
